Press releases
- Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
- Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
- Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
- Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
- Fulgent Reports First Quarter 2024 Financial Results
More ▼
Key statistics
As of last trade, Fulgent Genetics Inc (7F0:BER) traded at 20.80, 17.51% above the 52 week low of 17.70 set on Jun 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.40 |
---|---|
High | 21.00 |
Low | 20.40 |
Bid | 20.60 |
Offer | 21.00 |
Previous close | 20.40 |
Average volume | 40.33 |
---|---|
Shares outstanding | 29.92m |
Free float | 20.19m |
P/E (TTM) | -- |
Market cap | 668.51m USD |
EPS (TTM) | -5.57 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 18:37 BST.
More ▼